High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia

Grants

Funding Acknowledgements

Dr. Benjamin W. Teh is supported by a National Health and Medical Research Council Early Career fellowship and Peter MacCallum Cancer Centre clinical research fellowship. This study did not receive external funding. B.W.T has received speaker fees from Gilead. S.H has received an honorarium from Gilead and educational grant from Abbvie. C.S.T has received research funding and honorarium from Janssen and Abbvie and honorarium from Gilead. M.A.S has received research funding and honorarium from Merck Sharpe and Dohme and Gilead.